CLDN18 and gastroesophageal junction adenocarcinoma: This study investigated the prevalence of CLDN18.2 expression in patients with stages II-IV gastric cancer or gastroesophageal junction adenocarcinoma and its correlation with clinicopathologic features and other crucial biomarkers.